TRIUMPH-2 trial: triple agonist shows >20% weight loss in obesity and diabetes

The international TRIUMPH-2 trial, with Argentine participation, reported weight loss exceeding 20% in patients with obesity and type 2 diabetes using a triple agonist. This represents a significant advancement in obesity pharmacotherapy, potentially reshaping treatment paradigms. The results are preliminary and not yet peer-reviewed, but the magnitude of effect is notable.